<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04940871</url>
  </required_header>
  <id_info>
    <org_study_id>HUN-FAVI-02</org_study_id>
    <nct_id>NCT04940871</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of Favipiravir-HU</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Favipiravir-HU Compared to Placebo as add-on Therapy to Standard of Care in Asymptomatic to Mild Severity COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pecs</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hungarian Ministry of Innovation and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pecs</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the safety and efficacy of Favipiravir HU when administered&#xD;
      to SARS-Cov- 2 patients in order to offer a safe and effective treatment to SARS-Cov-2&#xD;
      infection during the pandemic. The study is not for registration purposes and is not part of&#xD;
      a series of studies for registration of Favipiravir HU.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>PRIM1_ the percentage of virus copy number</measure>
    <time_frame>5 months</time_frame>
    <description>The primary endpoint of the study is the percentage of virus copy number at Day6 compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SEC1_mortality rate</measure>
    <time_frame>6 months</time_frame>
    <description>Overall mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SEC2_respiratory failure</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients with respiratory failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SEC3_ intensive care</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients with need for intensive care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SEC4_non-invasive respiratory support</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients with need for non-invasive respiratory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SEC5_ invasive respiratory support</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients with need for invasive respiratory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SEC6_ Acute Respiratory Distress Syndrome</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients with Acute Respiratory Distress Syndrome</description>
  </secondary_outcome>
  <other_outcome>
    <measure>KSEC1_Time to virus elimination</measure>
    <time_frame>5 months</time_frame>
    <description>Number of days from treatment start to virus elimination</description>
  </other_outcome>
  <other_outcome>
    <measure>KSEC2_severe stages of COVID-19</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients achieving more severe stages of COVID-19</description>
  </other_outcome>
  <other_outcome>
    <measure>KSEC3_Time to recovery</measure>
    <time_frame>6 months</time_frame>
    <description>Time to recovery in patients who have developed symptoms</description>
  </other_outcome>
  <other_outcome>
    <measure>KSEC4_ adverse event</measure>
    <time_frame>6 months</time_frame>
    <description>Number and proportion of patients with at least 1 adverse event related to study treatment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</condition>
  <arm_group>
    <arm_group_label>Favipiravir HU + SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Favipiravir HU + SOC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo HU + SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo HU + SOC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Favipiravir HU 200 mg hard capsules</intervention_name>
    <description>Drug substance: Favipiravir Dose: 200 mg Administration: oral Formulation: capsules</description>
    <arm_group_label>Favipiravir HU + SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo HU</intervention_name>
    <description>Name: Placebo clinical sample Drug substance: placebo Dose: - Administration: oral Formulation: capsules</description>
    <arm_group_label>Placebo HU + SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients between the ages of 18 and 65 years.&#xD;
&#xD;
          2. Patients with PCR confirmed SARS-CoV-2 infection&#xD;
&#xD;
          3. Asymptomatic or have mild only symptoms and symptoms are onset less than 5 days&#xD;
&#xD;
          4. Signed Informed Consent Form and Patient Information Leaflet&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or possibly pregnant patients or lactating females&#xD;
&#xD;
          2. Patients have moderate to severe or immediately life-threatening COVID-19&#xD;
&#xD;
          3. Major risk factor onset (Obesity, Diabetes, COPD, Hypertension)&#xD;
&#xD;
          4. Patients with SpO2 less than 95% without oxygen therapy&#xD;
&#xD;
          5. Patients with severe hepatic impairment equivalent to Grade C on Child-Pugh&#xD;
             classification&#xD;
&#xD;
          6. Patients with renal impairment requiring dialysis&#xD;
&#xD;
          7. Patients with disturbed consciousness such as disturbed orientation&#xD;
&#xD;
          8. Female patients who are woman of childbearing potential and unable to consent to use&#xD;
             of dual contraception from the start of favipiravir administration to 30 days after&#xD;
             the end of favipiravir administration. Dual contraception is a combination of two of&#xD;
             the following: Barrier method of contraception: condoms (male or female) with&#xD;
             orwithout a spermicidal agent, diaphragm or cervical cap with spermicide; IUD;&#xD;
             Hormone-based contraceptive; Tubal ligation&#xD;
&#xD;
          9. Male patients whose are unable to consent to use of barrier method of contraception&#xD;
             (condom) the start of favipiravir administration to 90 days after the end of&#xD;
             favipiravir administration. Male patients who are planning to donate sperm in 90 days&#xD;
             after the start of favipiravir administration.&#xD;
&#xD;
         10. Patients with hereditary xanthinuria&#xD;
&#xD;
         11. Patient with severe uncontrolled hyperuricaemia&#xD;
&#xD;
         12. Patients receiving immunosuppressants&#xD;
&#xD;
         13. Patients who received interferon-alpha or drugs with reported antiviral activity&#xD;
             against SARS-CoV- 2 (hydroxychloroquine sulfate, chloroquine phosphate,&#xD;
             lopinavir-ritonavir combination, ciclesonide, nafamostat mesylate, camostat mesylate,&#xD;
             remdesivir, etc.) within 72 hours or Patients who receive forbidden concomitant&#xD;
             medication&#xD;
&#xD;
         14. Any medical condition that the examining physician deems unsuitable for the patient to&#xD;
             participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Krisztina Hr√°cs, PhD</last_name>
    <phone>+36205967957</phone>
    <email>krisztina.hracs@adwareresearch.com</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Favipiravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

